Leaflet VALKUBIT 97mg / 103mg film-coated tablets

Indicated for: hypertension

Route of administration: oral

Substance: sacubitril + valsartan (antihypertensive + angiotensin II receptor blocker)

ATC: C09DX04 (Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs), other combinations)

Precautions:
Dizziness / vertigo
Dizziness / vertigo

This medicine may cause dizziness or vertigo.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hypotension / fall risk
Hypotension / fall risk

May lower blood pressure and increase the risk of falls.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Electrolyte disturbances
Electrolyte disturbances

This medicine may change blood electrolyte levels.

Sacubitril+valsartan is a combination medication used in the treatment of chronic heart failure with reduced ejection fraction. Sacubitril is a neprilysin inhibitor, an enzyme that degrades natriuretic peptides, bradykinin, and other vasodilatory substances. By inhibiting neprilysin, sacubitril increases the levels of these substances, improving cardiac function. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure and reduces the workload on the heart.

This combination is taken orally, usually twice daily, and is indicated for patients with chronic heart failure to reduce the risk of hospitalization and cardiovascular mortality. It is considered an advanced therapy in heart failure management.

Common side effects include hypotension, hyperkalemia, dizziness, and renal impairment. In rare cases, severe adverse reactions such as angioedema may occur. Regular monitoring of blood pressure, renal function, and potassium levels is essential.

Sacubitril+valsartan represents an innovation in heart failure treatment, providing significant benefits in reducing symptoms and improving patients' quality of life.

General data about VALKUBIT 97mg / 103mg

  • Substance: sacubitril + valsartan
  • Date of latest medicines list: 01-01-2026
  • Product code: W71521001
  • Concentration: 97mg / 103mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 14
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: KRKA, D.D. NOVO MESTO - SLOVENIA
  • Holder: KRKA D.D, NOVO MESTO - SLOVENIA
  • Number: 16319/2025/01
  • Shelf life: 2 years

Pharmaceutical forms available for sacubitril + valsartan

Concentrations available for sacubitril + valsartan

  • 15mg/16mg
  • 24mg/26mg
  • 49mg/51mg
  • 6mg/6mg
  • 97mg/103mg